Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9561217 | GENENTECH INC | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(2 years ago) | |
US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
US7696326 | GENENTECH INC | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
Dec, 2027
(3 years from now) | |
US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(4 years from now) | |
US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(4 years from now) | |
US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(4 years from now) | |
US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(4 years from now) | |
US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(4 years from now) | |
US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(9 years from now) | |
US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(12 years from now) |
Esbriet is owned by Genentech Inc.
Esbriet contains Pirfenidone.
Esbriet has a total of 22 drug patents out of which 1 drug patent has expired.
Expired drug patents of Esbriet are:
Esbriet was authorised for market use on 11 January, 2017.
Esbriet is available in tablet;oral dosage forms.
Esbriet can be used as dosing 1602 mg/day pirfenidone following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf, method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer, dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis, dosage modification following grade 2 abnormality in biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then sub-1600 mg/day, then at least 1602 mg/day, pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen, administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder, method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer, method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer, discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone, method of administering pirfenidone capsules to treat a fibrotic condition, administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone, dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis, dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf, pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen, modifying pirfenidone administration from a dose of about 2400 mg/day downward by about 1600 mg/day while co-administering fluvoxamine to reduce drug interactions with fluvoxamine, discontinuing use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6 and then administering pirfenidone, method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis.
Drug patent challenges can be filed against Esbriet from 15 October, 2018.
The generics of Esbriet are possible to be released after 28 March, 2037.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for day...
Dosage: TABLET;ORAL